mdlinx mdlinx
Latest (98) Full Text Articles (3243) Focus on Pediatric Article Summary

Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty Full Text
JAMA Internal Medicine, 04/26/2012

De Luca G et al. – The present pooled patient–level meta–analysis demonstrates that among patients with ST–segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention, sirolimus–eluting and paclitaxel–eluting stents compared with bare–metal stents are associated with a significant reduction in target–vessel revascularization at long–term follow–up. Although there were no differences in cumulative mortality, reinfarction, or stent thrombosis, the incidence of very late reinfarction and stent thrombosis was increased with these Drug–Eluting stent.

► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

Last month's top read Top Articles of 2012

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Other Topics in Cardiology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close